申请人:Aqsens Health Oy
公开号:EP3916391A1
公开(公告)日:2021-12-01
The present disclosure relates to a method for detecting a prostate cancer related biomarker, comprising contacting the diluted sample with a modulating agent selected from a group consisting of sodium;3-hydroxy-4-[(2-hydroxynaphthalen-1-yl)diazenyl]naphthalene-1-sulfonate, sodium;3-hydroxy-4-[(1-hydroxynaphthalen-2-yl)diazenyl]-7-nitronaphthalene-1-sulfonate, triisopropylsilane, and iron(III) chloride, and a luminescent label to obtain a measurement sample. Then, the measurement sample is incubated for a period of time and excited thereafter. Time-resolved luminescence signal of the label in the measurement sample is measured, leading to an increased likelihood of prostate cancer of the human subject if the luminescence signal is at least 50 % higher than for a control sample from a human subject without prostate cancer.
本公开涉及一种检测前列腺癌相关生物标记物的方法,该方法包括将稀释样品与选自以下组别的调节剂接触3-羟基-4-[(2-羟基萘-1-基)偶氮]萘-1-磺酸钠、3-羟基-4-[(1-羟基萘-2-基)偶氮]-7-硝基萘-1-磺酸钠、三异丙基硅烷和氯化铁(III)以及发光标签组成的组中的调节剂接触,以获得测量样品。然后,将测量样品培养一段时间并激发。测量样品中标签的时间分辨发光信号,如果发光信号比没有前列腺癌的人体对照样品至少高出 50%,则人体患前列腺癌的可能性增加。